We were pleased to learn of Moulis et al's update on their experience with abatacept in three patients with relapsing polychondritis, particularly as their disease manifestations reflected the same manifestations suggested in our study to be of greatest interest for abatacept: chondritis and peripheral arthritis.1 Interestingly, one patient achieved a complete, while another achieved only a partial, corticosteroid-sparing response, and …